JP2023518518A5 - - Google Patents
Info
- Publication number
- JP2023518518A5 JP2023518518A5 JP2022557752A JP2022557752A JP2023518518A5 JP 2023518518 A5 JP2023518518 A5 JP 2023518518A5 JP 2022557752 A JP2022557752 A JP 2022557752A JP 2022557752 A JP2022557752 A JP 2022557752A JP 2023518518 A5 JP2023518518 A5 JP 2023518518A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- fusion protein
- masked
- linker
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993334P | 2020-03-23 | 2020-03-23 | |
| US62/993,334 | 2020-03-23 | ||
| US202163146567P | 2021-02-05 | 2021-02-05 | |
| US63/146,567 | 2021-02-05 | ||
| PCT/CA2021/050383 WO2021189139A1 (en) | 2020-03-23 | 2021-03-23 | Masked il12 fusion proteins and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518518A JP2023518518A (ja) | 2023-05-01 |
| JP2023518518A5 true JP2023518518A5 (https=) | 2024-04-01 |
| JP7773991B2 JP7773991B2 (ja) | 2025-11-20 |
Family
ID=77890776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557752A Active JP7773991B2 (ja) | 2020-03-23 | 2021-03-23 | マスクされたｉｌ１２融合タンパク質及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230122079A1 (https=) |
| EP (1) | EP4126972A4 (https=) |
| JP (1) | JP7773991B2 (https=) |
| KR (1) | KR20230024252A (https=) |
| CN (1) | CN115529826A (https=) |
| AU (1) | AU2021240872A1 (https=) |
| BR (1) | BR112022019020A2 (https=) |
| CA (1) | CA3147126A1 (https=) |
| MX (1) | MX2022011676A (https=) |
| WO (1) | WO2021189139A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| JP7771076B2 (ja) * | 2020-04-01 | 2025-11-17 | エクシリオ デベロップメント， インコーポレイテッド | マスクされたｉｌ－１２サイトカイン及びその切断産物 |
| WO2021207669A1 (en) | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| CA3178657A1 (en) * | 2020-05-19 | 2021-11-25 | William Winston | Activatable il-12 polypeptides and methods of use thereof |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| WO2022155263A2 (en) * | 2021-01-12 | 2022-07-21 | Askgene Pharma Inc. | Chimeric molecules comprising il-12 agonist polypeptide |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| AU2022314734A1 (en) | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| WO2023050006A1 (en) * | 2021-09-29 | 2023-04-06 | Zymeworks Bc Inc. | Modified interleukin p40 subunit proteins and methods of use thereof |
| EP4466290A4 (en) * | 2022-01-20 | 2026-02-11 | Repertoire Immune Medicines Inc | IL-12 FUSION PROTEINS TARGETING CD8 |
| US20250114489A1 (en) * | 2022-02-15 | 2025-04-10 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
| AU2023226005A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| WO2024148369A1 (en) * | 2023-01-07 | 2024-07-11 | Lyell Immunopharma, Inc. | Targeted il-12 affinity variants |
| US20240376170A1 (en) | 2023-01-11 | 2024-11-14 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| IL322055A (en) * | 2023-01-13 | 2025-09-01 | Regeneron Pharma | IL12 receptor agonists and methods of using them |
| EP4704979A1 (en) * | 2023-01-20 | 2026-03-11 | Boehringer Ingelheim International GmbH | Il-12 fc fusion proteins |
| TW202517789A (zh) * | 2023-07-04 | 2025-05-01 | 香港商禮邦醫藥（香港）有限公司 | Ｋｌｋ１融合蛋白質的製備方法 |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| CN119823266A (zh) * | 2023-10-13 | 2025-04-15 | 英脉德医疗科技(广东)有限公司 | 肿瘤微环境特异激活的cd47抗体 |
| TW202523680A (zh) * | 2023-12-07 | 2025-06-16 | 大陸商上海藥明生物技術有限公司 | 針對ｉｌ－１２受體的異二聚體蛋白 |
| WO2025122957A1 (en) * | 2023-12-08 | 2025-06-12 | Amunix Pharmaceuticals, Inc. | Protease activatable cytokines and methods for making and using the same |
| WO2025136986A2 (en) | 2023-12-18 | 2025-06-26 | Genzyme Corporation | Il-12 loss of potency muteins |
| CN117838836B (zh) * | 2024-01-11 | 2024-06-28 | 广州医科大学附属第二医院 | 白介素39在防治血小板减少症中的应用 |
| WO2025160083A1 (en) * | 2024-01-22 | 2025-07-31 | Onko-Innate Pty Ltd | Targeted low potency il-12 fc fusion proteins and uses thereof |
| WO2025242836A1 (en) * | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) * | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026020161A1 (en) * | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2636046C2 (ru) * | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CN109071653A (zh) * | 2016-03-29 | 2018-12-21 | 詹森生物科技公司 | 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣 |
| BR112019005964A2 (pt) * | 2016-09-27 | 2019-06-18 | Epicentrx, Inc. | proteínas de fusão imunomoduladoras |
| EP3762406A2 (en) * | 2018-03-09 | 2021-01-13 | Askgene Pharma, Inc. | Cytokine prodrugs |
| WO2019222296A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| AU2019288484B2 (en) * | 2018-06-22 | 2024-06-20 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
| SG11202013248YA (en) * | 2018-07-31 | 2021-02-25 | Amgen Inc | Pharmaceutical formulations of masked antibodies |
| US20220002370A1 (en) * | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| WO2020160189A1 (en) * | 2019-01-29 | 2020-08-06 | Gritstone Oncology, Inc. | Multispecific binding proteins |
| AU2020353235A1 (en) * | 2019-09-28 | 2022-03-31 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
| CN110777115B (zh) | 2019-11-21 | 2020-08-21 | 北京启辰生生物科技有限公司 | 用于促进辅助T细胞产生TNF-α细胞因子的工程化DC细胞及方法 |
| WO2022016270A1 (en) * | 2020-07-20 | 2022-01-27 | Zymeworks Inc. | Fusion proteins comprising a ligand-receptor pair and a biologically functional protein |
-
2021
- 2021-03-23 JP JP2022557752A patent/JP7773991B2/ja active Active
- 2021-03-23 MX MX2022011676A patent/MX2022011676A/es unknown
- 2021-03-23 AU AU2021240872A patent/AU2021240872A1/en active Pending
- 2021-03-23 EP EP21776799.5A patent/EP4126972A4/en active Pending
- 2021-03-23 US US17/914,261 patent/US20230122079A1/en active Pending
- 2021-03-23 BR BR112022019020A patent/BR112022019020A2/pt unknown
- 2021-03-23 KR KR1020227036756A patent/KR20230024252A/ko active Pending
- 2021-03-23 CA CA3147126A patent/CA3147126A1/en active Pending
- 2021-03-23 CN CN202180030714.5A patent/CN115529826A/zh active Pending
- 2021-03-23 WO PCT/CA2021/050383 patent/WO2021189139A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518518A5 (https=) | ||
| US20250179141A1 (en) | Activatable cytokine constructs and related compositions and methods | |
| CN112534052B (zh) | 全新il-21前药及使用方法 | |
| JP2022536898A5 (https=) | ||
| CN114466657B (zh) | 包括蛋白酶激活治疗剂的组合物和方法 | |
| EP4017594A1 (en) | Novel il-21 prodrugs and methods of use thereof | |
| US11667687B2 (en) | Masked activatable interferon constructs | |
| JPH07501698A (ja) | 二価特異性ヘテロ二量体 | |
| EP4019536A1 (en) | Immunocytokine, preparation for same, and uses thereof | |
| CN116655799A (zh) | 包括可切割接头的il-2细胞因子前药 | |
| EP4284819A1 (en) | Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide | |
| CN102281891A (zh) | 白蛋白结合肽介导的疾病靶向 | |
| CN120051292A (zh) | Il-18融合蛋白以及生产il-18的方法 | |
| US20250353890A1 (en) | Clec9a-based chimeric protein complexes | |
| CN115175920A (zh) | 加条形码的xten多肽及其组合物以及其制备和使用方法 | |
| US20240400696A1 (en) | Compositions targeting epidermal growth factor receptor and methods for making and using the same | |
| EP4524159A1 (en) | Antibody and use thereof | |
| CN120958015A (zh) | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 | |
| US20230406927A1 (en) | Masked single-domain antibodies and methods thereof | |
| CN120936384A (zh) | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 | |
| US20240400630A1 (en) | Activatable cytokine constructs and related compositions and methods | |
| WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
| JP2023525555A5 (https=) | ||
| US20060051366A1 (en) | Use of soluble CD26 as inhibitor of angiogenesis and inflammation | |
| KR20240147814A (ko) | 인터루킨 12 수용체 변이체, 이를 포함하는 융합단백질 및 이의 용도 |